ALT Stock Overview
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Altimmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.37 |
| 52 Week High | US$14.84 |
| 52 Week Low | US$5.28 |
| Beta | 0.17 |
| 1 Month Change | -7.14% |
| 3 Month Change | -10.91% |
| 1 Year Change | -27.28% |
| 3 Year Change | -9.77% |
| 5 Year Change | 261.93% |
| Change since IPO | -97.32% |
Recent News & Updates
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?
Jan 15
Altimmune Could Find A Partner For Its Phase 3 Exercise
Dec 30Altimmune 2025: Redefining Obesity And MASH Treatment
Dec 16Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health
Nov 13Recent updates
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?
Jan 15Altimmune Could Find A Partner For Its Phase 3 Exercise
Dec 30Altimmune 2025: Redefining Obesity And MASH Treatment
Dec 16Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health
Nov 13Regulatory And Clinical Catalysts Ahead For Altimmune
Oct 28Consider Buying Potential Takeover Target Altimmune
Oct 02Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Sep 21We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Sep 12Altimmune: Emerging Position In Competitive Space, But Risks Remain
Aug 27Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note
Jun 24Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns
May 27Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Feb 12Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10Thoroughly Derisked, Altimmune Is Now A Great Buy
Jan 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth
Oct 27Altimmune: Overreaction On NASH Data Creates Buying Opportunity
Sep 15Reassessing Altimmune
Sep 07Altimmune sets new 52-week high on rising volume
Aug 31Altimmune Q2 2022 Earnings Preview
Aug 10Altimmune: Several Catalysts In 2 Large Market Indications This Year
Jun 29Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Jun 27Altimmune's New Avatar As A Liver Disease Player
Apr 07Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Feb 01Altimmune: Changing Focus To Pemvidutide In 2022
Jan 03Shareholder Returns
| ALT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.4% | 0.4% | 1.5% |
| 1Y | -27.3% | -2.7% | 22.4% |
Return vs Industry: ALT underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: ALT underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| ALT volatility | |
|---|---|
| ALT Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 59 | Vipin Garg | altimmune.com |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
Altimmune, Inc. Fundamentals Summary
| ALT fundamental statistics | |
|---|---|
| Market cap | US$453.06m |
| Earnings (TTM) | -US$103.52m |
| Revenue (TTM) | US$52.00k |
8,713x
P/S Ratio-4.4x
P/E RatioIs ALT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALT income statement (TTM) | |
|---|---|
| Revenue | US$52.00k |
| Cost of Revenue | US$79.35m |
| Gross Profit | -US$79.30m |
| Other Expenses | US$24.22m |
| Earnings | -US$103.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.46 |
| Gross Margin | -152,503.85% |
| Net Profit Margin | -199,076.92% |
| Debt/Equity Ratio | 0% |
How did ALT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 11:05 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Altimmune, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Joshua Schimmer | Evercore ISI |
| Liisa Bayko | Evercore ISI |